Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report.
Hepatocellular carcinoma
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
09
2021
accepted:
21
06
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma with neuroendocrine differentiation (HCC-NED) is a very rare subtype of primary liver cancer. Treatment allocation in these patients therefore remains a challenge. We report the case of a 74-year-old man with a HCC-NED. The tumor was surgically removed in curative intent. Histopathological work-up revealed poorly differentiated hepatocellular carcinoma (Edmondson-Steiner grade IV) with diffuse expression of neuroendocrine markers synaptophysin and chromogranin. Three months after resection, multifocal recurrence of the HCC-NED was observed. In the meantime, tumor organoids have been generated from the resected HCC-NED and extensively characterized. Sensitivity to a number of drugs approved for the treatment of HCC or neuroendocrine carcinomas was tested in vitro. Based on the results of the in vitro drug screening, etoposide and carboplatin are used as first line palliative combination treatment. With genomic analysis revealing a The rapid establishment of patient-derived tumor organoids allows in vitro drug testing and thereby personalized treatment choices, however clinical translation remains a challenge. To the best of our knowledge, this report provides a first proof-of-principle for using organoids for personalized medicine in this rare subtype of primary liver cancer.
Sections du résumé
Background
UNASSIGNED
Hepatocellular carcinoma with neuroendocrine differentiation (HCC-NED) is a very rare subtype of primary liver cancer. Treatment allocation in these patients therefore remains a challenge.
Methods
UNASSIGNED
We report the case of a 74-year-old man with a HCC-NED. The tumor was surgically removed in curative intent. Histopathological work-up revealed poorly differentiated hepatocellular carcinoma (Edmondson-Steiner grade IV) with diffuse expression of neuroendocrine markers synaptophysin and chromogranin. Three months after resection, multifocal recurrence of the HCC-NED was observed. In the meantime, tumor organoids have been generated from the resected HCC-NED and extensively characterized. Sensitivity to a number of drugs approved for the treatment of HCC or neuroendocrine carcinomas was tested in vitro.
Results
UNASSIGNED
Based on the results of the in vitro drug screening, etoposide and carboplatin are used as first line palliative combination treatment. With genomic analysis revealing a
Conclusion
UNASSIGNED
The rapid establishment of patient-derived tumor organoids allows in vitro drug testing and thereby personalized treatment choices, however clinical translation remains a challenge. To the best of our knowledge, this report provides a first proof-of-principle for using organoids for personalized medicine in this rare subtype of primary liver cancer.
Identifiants
pubmed: 35789568
doi: 10.1038/s43856-022-00150-3
pii: 150
pmc: PMC9249908
doi:
Types de publication
Journal Article
Langues
eng
Pagination
80Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interest.
Références
Nat Med. 2013 Nov;19(11):1469-1472
pubmed: 24162815
Nat Commun. 2020 Apr 20;11(1):1897
pubmed: 32312968
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Am J Surg Pathol. 2017 Nov;41(11):1547-1551
pubmed: 28719467
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
J Med Chem. 2016 Apr 14;59(7):3392-408
pubmed: 27003761
Nat Genet. 2012 May 27;44(7):760-4
pubmed: 22634756
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Am J Surg Pathol. 2018 Jul;42(7):927-935
pubmed: 29683818
BioData Min. 2017 Jan 26;10:2
pubmed: 28149325
J Clin Pathol. 2017 Jul;70(7):563-570
pubmed: 27881473
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
Med (N Y). 2021 Sep 10;2(9):1011-1026
pubmed: 34617071
Science. 2011 Mar 4;331(6021):1199-203
pubmed: 21252315
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Semin Diagn Pathol. 2006 May;23(2):70-83
pubmed: 17193820
Exp Mol Pathol. 2017 Oct;103(2):200-203
pubmed: 28939160
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Cancer. 1954 May;7(3):462-503
pubmed: 13160935
J Hepatol. 2020 Dec;73(6):1460-1469
pubmed: 32710922
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
NPJ Precis Oncol. 2021 Apr 12;5(1):30
pubmed: 33846504
World J Surg Oncol. 2021 Mar 16;19(1):78
pubmed: 33726764
Cell Rep. 2018 Jul 31;24(5):1363-1376
pubmed: 30067989
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Endocr Pathol. 2016 Dec;27(4):284-311
pubmed: 27169712
Cell. 2020 Nov 25;183(5):1420-1435.e21
pubmed: 33159857
Gastroenterol Clin North Am. 2017 Jun;46(2):365-391
pubmed: 28506370
Hepatology. 2014 Dec;60(6):1972-82
pubmed: 24798001
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
Pathol Res Pract. 2017 Oct;213(10):1322-1326
pubmed: 28647212
JHEP Rep. 2020 Oct 22;3(1):100198
pubmed: 33241206
Cancer Discov. 2017 May;7(5):462-477
pubmed: 28331002
Cancer Cell. 2014 Apr 14;25(4):428-41
pubmed: 24735922
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Nat Med. 2017 Dec;23(12):1424-1435
pubmed: 29131160